rs3753394 Complement Factor H (CFH) Gene Polymorphism in Patients with Age-Related Macular Degeneration (AMD) in Indonesian Population

Supanji Supanji1, Ayudha Bahana Ilham Perdanaia1, Dinda Ajeng Anindita1, Tri Wahyu Widayanti1, Firman Setya Wardhana1, Muhammad Bayu Sasongko1, Mohammad Eko Prayogo1, Angela Nurini Agni2, and Chio Oka2

1Department of Ophthalmology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Sekip Utara, Yogyakarta 55281, Indonesia
2Laboratory of Gene Function in Animals, Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara 630-0192, Japan

Abstract. Neovascular Age-related Macular Degeneration (nAMD) is one of the major factors for blindness and impaired visual acuity in elderly people. The aim of this study was CFH gene screening in Age-Related Macular Degeneration patients in Indonesia. This study was performed in 106 AMD patients and 104 controls for genomic markers in the Complement Factor H (CFH). The diagnosis of AMD was carried out by retinal specialists based on color fundus photography and optical coherence tomography. Informed consent was given to patients then proceed to blood sampling and recording of body parameters (BMI, smoking, other systemic diseases). CFH polymorphisms were then analyzed by PCR-restriction fragment length polymorphism (PCR-RFLP). There was no association between genetics polymorphism with nAMD. From the research can be inferred that association between genetics polymorphism with nAMD was insignificant.

1 Introduction

Neovascular Age-related macular degeneration (nAMD) was the serious risk factor in elderly people central sight loss in developed countries [1], [2] Approximately 200 millions people had AMD in 2020. The number was predicted to be increased to 288 millions in 2040. AMD’s risk is primarily caused by advanced age and was also influenced by DNA mutations as well as lifestyle.[3]–[5]

Polymorphism in complement gene family, in particular, were closely related to the AMD epidemiology and biology.[4], [6]–[15]. Complement was essentials part of innate immune system which involved in opsonizing, removing bacteria and death cell degradation. Complement factor also involved in immune cells recognition to infection and tissue injury sites.[16], [17].

The significance factors of complement protein in AMD onset remains uncertain. In case lampalizumab, a factor D inhibitor which inhibit of the alternative complement pathway activation, was fail in a phase III clinical trial. Lampalizumab had no effect on the halting progression of drusen enlargement in severe dry AMD patients [18].

The genetic correlations in AMD have been extensively documented in the literature[10], [12], [19]. The Y402H mutation in complement factor H (CFH) [20]–[24] was one of the most widely studied and replicated genetic variations linked to AMD risk.

In Western populations, CFH connections were found in Dutch, American, Italian, Spanish, and Swiss people are a few examples. Similar relationships have been seen in Asian populations such Japanese[25], Chinese[26], [27], and Indians[28]. However, evidence from Asia’s Malay community, which is one of Asia’s major ethnic groups, is few. An earlier study in Indonesia found a link between Y402H amd AMD [20].

The aim of this study was to look at the relationship between rs3753394 CFH and AMD in the Indonesian population.

2 Methods

2.1 Patient recruitment and data collection

The research procedure related to patients was approved by the Ethics Committee (Ref. No.: KE/FK/021/EC/2021). During patient and control screening, 106 eligible AMD and 104 age-matched subjects were recruited. Patient and control were screened from January to August 2019. All participants were understood and signed the informed consent before ophthalmic test and blood collection. To avoid interference, the authors only recruit patients who have no additional retinal or systemic disorders. To diagnose nAMD or confirm the control eye group, all patients receive a complete ophthalmic test that includes BCVA, fundoscopy, and optical coherence tomography (OCT).
This investigation employed spectral-domain OCT in separating nAMD from polypoidal choroidal vasculopathy (PCV). When compared to ICGA, the diagnosis of nAMD exceeded 90% matching data, indicating that there was minimal bias in this investigation.

A systematic questionnaire was utilized to assessed AMD and control patients’ lifestyles, smoking status, and working activity.

2.2 Genotyping

Each patient’s DNA was isolated from venous blood which stored in vacotainer containing EDTA. In this research, DNA extraction kit (GeneAid Genomic Human DNA Mini Kit [GB100/300], New Taipei City, Taiwan) was used to process the blood samples. The specific variants rs3753394 was amplified using thermal cycler. The machine was set as 1 cycle (95 °C for 10 min), 30 cycles (95 °C for 30 s; 55 °C for 60 s; 72 °C for 60 s), and 1 cycle (72 °C for 5 min). The primer used in this research was F: 5’-CACAATAGACCCGAATAGAGT-3’ and R: 5’-GAAATGCCAGAAGTTAAACC-3’ [29].

The PCR product was digested using EcoRV for genotype determination (Figure 1). The PCR product was incubated at 37 °C for 18 h. The digested PCR products were run on 2% agarose gel.

2.3 Statistical analysis

Data analysis was done using Crosstabs (Chi-square tests) and logistic regression models measured by odds ratio (OR) and 95% confidence interval (CI). All analyses were carried out using SPSS (version 25, IBM Corp).

3 Results

An ophthalmologist made the diagnosis of all AMD or age-matched controls. 104 nAMD patients [46 males (44.2%) and 58 females (55.8%)] and 100 age-matched controls [45 males (45.0%) and 55 females (55.0%)] data were included for statistical analysis, shown in Table 1.

Table 1. Baseline characteristics of nAMD and age-matched control

| Gender | nAMD (n=104) | Control (n=100) | P |
|--------|--------------|----------------|---|
| Male   | 46 (44.2%)   | 45 (45.0%)     | 0.91 |
| Female | 58 (55.8%)   | 55 (55.0%)     |     |

| Age, year | nAMD (n=104) | Control (n=100) | P |
|-----------|--------------|----------------|---|
| 40-49     | 6 (5.8%)     | 1 (1.0%)       | 0.16 |
| 50-59     | 20 (19.2%)   | 7 (7.0%)       |     |
| 60-69     | 35 (33.7%)   | 50 (50.0%)     |     |
| 70-79     | 39 (37.5%)   | 38 (38.0%)     |     |
| >80       | 4 (3.8%)     | 4 (4.0%)       |     |

| Race      | nAMD (n=104) | Control (n=100) | P |
|-----------|--------------|----------------|---|
| Javanese  | 97 (93.3%)   | 97 (97.0%)     | 0.18 |
| Non-Javanese | 7 (6.7%) | 3 (3.0%)       |     |

| Genotype | nAMD (n=104) | Control (n=100) | Genotype Distribution | Genotype Association (p) | OR | 95% CI |
|----------|--------------|----------------|-----------------------|-------------------------|----|--------|
| GT       | 33 (55%)     | 27 (45%)       | 0.540 0.82            | 0.43 1.56                |    |
| TT       | 50 (50%)     | 50 (50%)       | 0.802 1.095           | 0.54 2.23                |    |
| GG       | 21 (47.7%)   | 23 (52.3%)     | – 1.00                | Ref                     |    |

Table 2 summarizes the genotype distributions, genotype associations, odds ratio (OR), and 95% confidence interval of CFY Y402H. The GG genotype is used as indicator. It is worth noting that the TT genotype is the most prevalent in both groups, whereas the GG genotype is the least common. Both GT and TT genotypes have p>0.05 indicates that they were not significantly associated.

4 Discussions

The findings of this investigation revealed that CFH polymorphisms were not significantly linked to AMD. rs3753394 was not associated with nAMD in Indonesia. Our results similar to Japan[30], Spanish[31], but not to Korea[32] Caucasian[12] and China[26], [33] population. These results indicated that this SNP is not specific and cannot be determined as marker in Malay race.
rs3753394 mutation occur in the promoter region of \textit{CFH} which regulate the gene expression. In another epidemiological study, rs3753394 is among the strong SNPs beside rs1061170 (Y402H), rs10737680 and rs800292 (I62V) within \textit{CFH} gene.

Complement Factor H (\textit{CFH}) was the most associated genes beside \textit{ARMS2} and \textit{HTRA1} in nAMD. Despite the fact that additional variables may play a role in AMD pathogenesis, complement regulatory pathways could be viable therapeutic targets in nAMD.

Our study’s strengths are the age-matched participant, extensive ophthalmic examinations by vitreo-retina specialists employing modern multimodal imaging to confirm the diagnosis of nAMD. Genotyping was utilized PCR-RFLP to assure genetic assessment accuracy.

Another drawback of our study is that because it was conducted in a hospital, the advanced profile of AMD patients may have been captured, and so the representation of AMD in the general community is limited. It's still unclear whether people with AMD in the broader community have comparable genetic correlations. To answer these problems, further population-based research is needed.

## 5 Conclusion

The rs3753394 \textit{CFH} gene polymorphism was neither statistically or clinically significant in persons with AMD in Yogyakarta, Indonesia, according to this study. We are aware that the patient group's short sample size may have resulted in poorer statistical power, and that a larger and more diversified sample size would have been preferable to allow sub-analysis based on Indonesia's ethnic origin for future studies.

The authors would like to acknowledge the Directorate of Research, Universitas Gadjah Mada for providing the RTA grant 2021 (No: 3143/UN1.P.3/DRPT/PT/2021).

## References

[1] J. B. Jonas, “Global prevalence of age-related macular degeneration,” \textit{The Lancet Global Health}, vol. 2, no. 2. Elsevier, pp. e65–e66, Feb. 01, 2014, doi: 10.1016/S22214-109X(13)70163-3.

[2] W. L. Wong et al., “Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis,” \textit{Lancet Glob. Heal.}, vol. 2, no. 2, pp. e106–e116, Feb. 2014, doi: 10.1016/S22214-109X(13)70145-1.

[3] N. G. Lambert et al., “Risk factors and biomarkers of age-related macular degeneration,” \textit{Prog. Retin. Eye Res.}, vol. 54, pp. 64–102, Sep. 2016, doi: 10.1016/j.preteyeres.2016.04.003.

[4] L. G. Friscia, R. N. Fariss, D. Stambolian, G. R. Abecasis, C. A. Curcio, and A. Swaroop, “Age-related macular degeneration: Genetics and biology coming together,” \textit{Annual Review of Genomics and Human Genetics}, vol. 15. Annual Reviews Inc., pp. 151–171, 2014, doi: 10.1146/annurev-genom-090413-025610.

[5] E. Y. Chew et al., “Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report No. 36,” \textit{JAMA Ophthalmol.}, vol. 132, no. 3, pp. 272–277, 2014, doi: 10.1001/jamaophthalmol.2013.6636.

[6] D. Iejima et al., “HTRA1 (high temperature requirement a serine peptidase 1) gene is transcriptionally regulated by insertion/deletion nucleotides located at the 3’ end of the \textit{ARMS2} (age-related maculopathy susceptibility 2) gene in patients with age-related macular degener,” \textit{J. Biol. Chem.}, vol. 290, no. 5, pp. 2784–2797, Jan. 2015, doi: 10.1074/jbc.M114.593384.

[7] M. Fleckenstein et al., \textit{Age-related macular degeneration}, vol. 7, no. 1. 2021.

[8] G. Wang et al., “Analysis of the indel at the \textit{ARMS2} 3’UTR in age-related macular degeneration,” \textit{Hum. Genet.}, vol. 127, no. 5, pp. 595–602, Mar. 2010, doi: 10.1007/s00439-010-0805-8.

[9] L. G. Fritsche et al., “A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants,” \textit{Nat. Genet.}, vol. 48, no. 2, pp. 134–143, Feb. 2016, doi: 10.1038/ng.3448.

[10] R. J. Klein et al., “Complement factor H polymorphism in age-related macular degeneration,” \textit{Science (80-. ).}, vol. 308, no. 5720, pp. 385–389, Apr. 2005, doi: 10.1126/science.1109557.

[11] A. O. Edwards, R. Ritter, K. J. Abel, A. Manning, C. Panhuysen, and L. A. Farrer, “Complement factor H polymorphism and age-related macular degeneration,” \textit{Science (80-. ).}, vol. 308, no. 5720, pp. 421–424, Apr. 2005, doi: 10.1126/science.1110189.

[12] J. L. Haines et al., “Complement factor H variant increases the risk of age-related macular degeneration,” \textit{Science (80-. ).}, vol. 308, no. 5720, pp. 419–421, Apr. 2005, Accessed: Jun. 21, 2021. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/15761120/.

[13] S. Raychaudhuri et al., “A rare penetrant mutation in \textit{CFH} confers high risk of age-related macular degeneration,” \textit{Nat. Genet.}, vol. 43, no. 12, pp. 1232–1236, Dec. 2011, doi: 10.1038/ng.976.

[14] J. B. Maller, J. A. Fagerness, R. C. Reynolds, B. M. Neale, M. J. Daly, and J. M. Seddon, “Variation in complement factor 3 is associated with risk of age-related macular degeneration,” \textit{Nat. Genet.}, vol. 39, no. 10, pp. 1200–1201, Oct. 2007, doi: 10.1038/ng2131.

[15] B. Gold et al., “Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular
degeneration,” Nat. Genet., vol. 38, no. 4, pp. 458–462, Apr. 2006, doi: 10.1038/ng1750.

[16] D. Hadley et al., “Analysis of six genetic risk factors highly associated with AMD in the region surrounding ARMS2 and HTRA1 on chromosome 10, region q26,” Invest. Ophthalmol. Vis. Sci., vol. 51, no. 4, pp. 2191–2196, Apr. 2010, doi: 10.1167/iovs.09-3798.

[17] F. Ricci et al., “Typing of ARMS2 and CFH in age-related macular degeneration: Case-control study and assessment of frequency in the Italian population,” Arch. Ophthalmol., vol. 127, no. 10, pp. 1368–1372, Oct. 2009, doi: 10.1001/archophthalmol.2009.237.

[18] L. G. Fritsche et al., “Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA,” Nat. Genet., vol. 40, p. 892, May 2008, [Online]. Available: https://doi.org/10.1038/ng.170.

[19] G. S. Hageman et al., “A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration,” Proc. Natl. Acad. Sci., vol. 102, no. 20, pp. 7227–7232, May 2005, doi: 10.1073/PNAS.0501356102.

[20] P. N. Baird, F. M. A. Islam, A. J. Richardson, M. Cain, N. Hunt, and R. Guymer, “Analysis of the Y402H variant of the complement factor H gene in age-related macular degeneration,” Invest. Ophthalmol. Vis. Sci., vol. 47, no. 10, pp. 4194–4198, Oct. 2006, doi: 10.1167/iovs.05-05128.

[21] S. J. Teper, A. Nowinska, and E. Wylegala, “A69S and R38X ARMS2 and Y402H CFH gene polymorphisms as risk factors for neovascular age-related macular degeneration in Poland - a brief report,” Med. Sci. Monit., vol. 18, no. 2, pp. PR1-3, Feb. 2012, doi: 10.12659/MSM.882447.

[22] M. H. Jabbarpoor Bonyadi, M. Yaseri, H. Nikkhah, M. Bonyadi, and M. Soheilian, “Association of risk genotypes of ARMS2/LOC387715 A69S and CFH Y402H with age-related macular degeneration with and without reticular pseudodrusen: a meta-analysis,” Acta Ophthalmol., vol. 96, no. 2, pp. e105–e110, Mar. 2018, doi: 10.1111/aos.13494.

[23] S. Supanji et al., “Associations of arsm2 and cfh gene polymorphisms with neovascular age-related macular degeneration,” Clin. Ophthalmol., vol. 15, pp. 1101–1108, 2021, doi: 10.2147/OPHT.S298310.

[24] H. N. Khanamiri et al., “Complement factor H Y402H and LOC387715 A69S polymorphisms in association with age-related macular degeneration in Iran,” J. Ophthalmic Vis. Res., vol. 9, no. 2, p. 181, 2014.

[25] M. Sakurai, T. Higashide, M. Takahashi, and K. Sugiyama, “Association between Genetic Polymorphisms of the Prostaglandin F2α Receptor Gene and Response to Latanoprost,” Ophthalmology, vol. 114, no. 6, pp. 1039–1045, Jun. 2007, doi: 10.1016/j.ophtha.2007.03.025.

[26] T. K. Ng et al., “Multiple Gene Polymorphisms in the Complement Factor H Gene Are Associated with Exudative Age-Related Macular Degeneration in Chinese,” Invest. Ophthalmol. Vis. Sci., vol. 49, no. 8, pp. 3312–3317, Aug. 2008, doi: 10.1167/IOVS.07-1517.

[27] Y. Gong et al., “Association of HTRA1 and CFH gene polymorphisms with age-related macular degeneration in Ningbo, China,” Int. Ophthalmol., vol. 41, no. 3, pp. 995–1002, Mar. 2021, doi: 10.1007/s10792-020-01655-3.

[28] P. Sundaresan et al., “Polymorphisms in ARMS2/HTRA1 and complement genes and age-related macular degeneration in India: Findings from the INDEYE study,” Invest. Ophthalmol. Vis. Sci., vol. 53, no. 12, pp. 7492–7497, Nov. 2012, doi: 10.1167/iovs.12-10073.

[29] D.-F. Zhang, X.-Q. Huang, D. Wang, Y.-Y. Li, and Y.-Gong Yao, “Genetic variants of complement genes Ficolin-2, Mannose-binding lectin and Complement Factor H are associated with leprosy in Han Chinese from Southwest China,” doi: 10.1007/s00439-013-1273-8.

[30] N. Gotoh et al., “No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese,” Hum. Genet., vol. 120, no. 1, pp. 139–143, May 2006, doi: 10.1007/s00439-006-0187-0.

[31] A. García-Layana, F. Cabrera-López, J. García-Arumí, L. Arias-Barquet, and J. M. Ruiz-Moreno, “Early and intermediate age-related macular degeneration: Update and clinical review,” Clin. Interv. Aging, 2017, doi: 10.2147/CIA.S142685.

[32] N. R. Kim, J. H. Kang, O. W. Kwon, S. J. Lee, J. H. Oh, and H. S. Chin, “Association between complement factor H gene polymorphisms and neovascular age-related macular degeneration in Koreans,” Invest. Ophthalmol. Vis. Sci., vol. 49, no. 5, pp. 2071–2076, May 2008, doi: 10.1167/iovs.07-1195.

[33] L. J. Chen et al., “Association of complement factor H polymorphisms with exudative age-related macular degeneration,” Mol. Vis., vol. 12, pp. 1536–1542, 2006, doi: 10.1016/j.ajo.2006.12.019.